SUBSIDIARY #2
DFP
-
GDE – Deals, Funding and Partnerships – Early Stage Start Ups in need for funding: Biologics, Small Molecules, Diagnostics and Medical Devices
http://pharmaceuticalintelligence.com/joint-ventures/
HQS – Boston, MA
HQS – Lausanne, Switzerland, Gerard Loiseau, ESQ – Business Development
- Corporate Clients for our Services
- Funding Cardiovascular Medical Devices Development
- Funding Biologics Development
- Funding Diagnostics
- Funding Partnerships in IP Development
- M&A and Exit
- Targeting Penetration in New Markets for High Technology Products
- Modeling the Management of Intellectual Property Royalties
SIX TYPES of Investments are representing Business Opportunities in Subsidiary #2
1. Investment in the form of Seed Money to develop a Product Concept
Ongoing Projects:
1.1 Dr. Rosalind Codrington, Cambridge, UK, Diagnostics Kit for Skin Cancer
1.2 Every Product concept of Dr. Justin D Pearlman
For M3DP – TWO inventions
1.2.1 A Product Concept to StopMI
1.2.2 A Product Concept for a Robotic Glove
For Joint Venture: SBH & M3DP – he has TWO inventions
1.2.3 A Product Concept for a “Cell BioFactory” for Diabetes
1.2.4 A Product Concept for an Artificial Kidney
1.3 Three Medical (Cardiovascular) Product Concept with US Patents issued to Bill Zurn, for Commercialization we requests $10Million, $10Million and $22Million
2. Investment in milestones for Products in Pre-Clinical Trials
2.1 ValveCure, Transition from Animal Trials to Human Trials or M&A
2.2 BioTerm Therapeutics (Dr. Shamir) – two drug-devices in OBGYN: Biologics and Multi needle circular syringe
2.2.1 prevent early delivery
2.2.2 induce early Labor
2.3 Telerescue (Dr. Shamir) a defibrillator, wearable Digital Medical Device for arrhythmia
2.4 Woodland Pharmaceuticals (Dr. Briggs and Dr. Raphael Nir) development of Biologics for
2.4.1 Brain Cancer, Multiform Gliomas
2.4.2 Liver Cancer: Anti Liver Fibrosis
3. Investment in milestones for Start Ups in Clinical Trials Phase
4. Investment in U.S. AND INTERNATIONAL PATENTS
4.1 Three U.S. Patents of Dr. Pearlman issued PRIOR to affiliation with LPBI
4.2 Three Medical U.S. Patents of Bill Zurn
4.3 All Other non-Medical U.S. Patents of Bill Zurn
5. Sales Outright – Acquisition of a Platform Informational Systems
5.1 New Medicine/OncologyKnowledgeBase – Global Relational Database Oncology Drugs and Clinical Trials, the one and ONLY in existence in Private Ownership
6. Investment in a PROFITABLE U.S. Biotech company
6.1 SBH Sciences, Inc. CEO and Owner, Dr. Raphael Nir, 10$ Sales Annually seeking $15Million investment for three Ventures, as follows:
1. SBH
Dr. Raphael Nir, CEO, Founder and Chairman
It is more accurate to “call” it : Galectin Sciences. It is a JV: SBH Sciences has 50% and Galactin Therapeutics has 50%.
The indication : Liver Fibrosis (NASH) : I assume $5M will advance us to IND.
- Automatics Western Blot capabilities.
We have perform the following (9 case studies with all the data at: http://www.sbhdiagnostics.com/Simple_Western_Studies.asp):
- Drug Effect On Protein Phosphorylation
- Characterization Of Biotherapeutics
- Drug Response Measurement
- Identification Of Clinical Trial Patient Response
- Monoclonal Antibody Analysis
- Drug Response Time Course
- Calculating Concentration of Unknown Biomarker
- Optimization of Biomarker Recovery
- Knockdown Experiment Using siRNA
2. Woodland Pharmaceuticals
http://woodlandbiosciences.com/Partners.asp
Dr. Raphael Nir, Co-Founder & CEO SBH Sciences
Woodland Biosciences is a strategic alliance between SBH Sciences, Woodland Pharmaceuticals and other partners, doing business as (DBA) Woodland Biosciences.
I assume $5M will advance us to IND for GBM.
We have also another indication : Pancreatic cancer . Similarly, $5M will advance us to IND.
We are seeking an Investment House to fund my Client-Companies
We are seeking to split my Finders Fee to get the funding accomplished
- GDE – Deals, Funding and Partnerships – Private Equity for 20 Early Stage Start Ups: Biologics, Small Molecules and Medical Devices
2012pharmaceutical
sjwilliamspa